Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

Xie et al., NCT04931004, NCT04931004, Feb 2022

Chlorhexidine

52nd treatment shown to reduce risk in November 2023, now with p < 0.00000000001 from 5 studies.

Lower risk for progression, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,200+ studies for 200+ treatments. c19early.org

Download Meta Analysis

Estimated 90 patient chlorhexidine early treatment RCT with results not reported over 3 years after estimated completion.

3 chlorhexidine RCTs have results missing long after expected1-3
The trials report a total of 383 patients, with 2 trials having actual enrollment of 293, and the other estimated.

Important missing comments or errors? Let us know.

Study covers chlorhexidine, cetylpyridinium chloride, and hydrogen peroxide.

1. Keating et al., SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD), NCT04478019, clinicaltrials.gov/study/NCT04478019clinicaltrials.gov.

2. Xie et al., Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection, NCT04931004, clinicaltrials.gov/study/NCT04931004clinicaltrials.gov.

3. Mira et al., Evaluation of the Efficacy of Mouth Rinses With Commercial Mouthwashes to Decrease Viral Load in Saliva in COVID-19 Patients, NCT05543603, clinicaltrials.gov/study/NCT05543603clinicaltrials.gov.

Xie et al., 28 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, trial NCT04931004 (history).